EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Patient versus physician preferences for lipid‐lowering drug therapy: A discrete choice experiment

Lingli Zhang iD, Jiali Chen, Zhaoliu Cao, Mengdie Zhang, Rui Ma, Pei Zhang, Guiqing Yao, Xin Li iD

Health Expectations · 2024-04 · 27 (2)

DOI: 10.1111/hex.14043 ↗

At a glance

Journal article in Health Expectations, published online on 2024-04-08. Written by Lingli Zhang and 7 co-authors. Institution: Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, China. Major MEDLINE topics: Physicians, Muscular Diseases, Dyslipidemias. Cited 14 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY 4.0). Funded by: Jiangsu Province Postgraduate Research and Practice Innovation Program, National Natural Science Foundation of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

The emergence of proprotein convertase subtilisin/kexin type 9 inhibitors offered dyslipidemia patients an alternative to statins for lipid‐lowering treatment. Understanding patient and physician preferences for lipid‐lowering drugs may promote shared decision‐making and improve treatment outcomes.

Methods

This study utilized an online discrete choice experiment (DCE) to assess the relative importance (RI) of six attributes related to lipid‐lowering drugs, including frequency of administration, mode of administration, reduction of low‐density lipoprotein cholesterol (LDL‐C) level, risk of myopathy, risk of liver damage, and out‐of‐pocket monthly cost. Respondents were recruited from dyslipidemia patients and cardiovascular physicians in China. A mixed logit model and latent class analysis were employed to estimate the preference coefficient, marginal willingness to pay (mWTP), and RI of attributes. Ethical approval has been obtained for this study.

Results

A total of 708 patients and 507 physicians participated in the survey. Patients prioritized the ‘risk of liver damage’ (RI = 23.6%) with ‘mode of administration’ (RI = 19.2%) and ‘frequency of administration’ (RI = 18.8%) following closely. Contrarily, physicians prioritized the ‘reduction of LDL‐C level’ (RI = 33.5%), followed by ‘risk of liver damage’ (RI = 26.0%) and ‘risk of myopathy’ (RI = 16.1%). Patients placed a higher value on ‘frequency of administration’ ( p < .001) and ‘mode of administration’ ( p < .001) compared to physicians, while physicians valued ‘reduction of LDL‐C level’ ( p < .001) and ‘risk of myopathy’ ( p = .012) more than patients. Physicians exhibited higher mWTP than patients for all attributes except frequency and mode of administration. The LCA revealed three distinct patient classes: focus on oral administration, focus on hepatic safety and frequency and focus on hepatic safety and cost. Likewise, three physician classes were identified: frequency‐insensitive, efficacy‐focused and safety‐focused.

Conclusions

The preferences for lipid‐lowering drug therapy differed between patients and physicians in China. Physicians should take into account patients' preferences and provide personalized treatment when they formulate lipid‐lowering treatment plans. Patient or Public Contribution Patients participated in the questionnaire design process. They engaged in a focus group discussion to determine attributes and levels and also participated in a pilot survey to assess the comprehensibility of the questionnaires. Additionally, patients were involved in the DCE survey to express their preferences. The findings of patient preference for lipid‐lowering drug therapy will promote shared decision‐making and optimize the treatment regimen.

Subjects

MeSH terms (MEDLINE)

PhysiciansMuscular DiseasesDyslipidemiasHumansPharmaceutical PreparationsCholesterol, LDLPatient PreferenceChoice Behavior

Author keywords

discrete choice experimentlipid‐lowering drugpreferences

Substances

Pharmaceutical PreparationsCholesterol, LDL

Authors and institutions

  • Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, China.
  • Department of Health Policy, School of Health Policy and Management, Nanjing Medical University, Nanjing, China.
  • Department of Pharmacy, Nanjing City Qixia District Hospital, Nanjing, China.
  • Department of Cardiovascular Sciences and Leicester Clinical Trial Unit, College of Life Sciences, University of Leicester, Leicester, UK.
  • Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.

ORCID profiles: Lingli Zhang, Xin Li

Funding

  • Jiangsu Province Postgraduate Research and Practice Innovation Program
  • National Natural Science Foundation of China

Cite

APA

Zhang, L., Chen, J., Cao, Z., Zhang, M., Ma, R., Zhang, P., Yao, G., & Li, X. (2024). Patient versus physician preferences for lipid‐lowering drug therapy: A discrete choice experiment. Health Expectations, 27(2). https://doi.org/10.1111/hex.14043

Vancouver

Zhang L, Chen J, Cao Z, Zhang M, Ma R, Zhang P, et al. Patient versus physician preferences for lipid‐lowering drug therapy: A discrete choice experiment. Health Expectations. 2024;27(2). doi:10.1111/hex.14043

BibTeX
@article{Zhang2024,
  author = {Zhang, Lingli and Chen, Jiali and Cao, Zhaoliu and Zhang, Mengdie and Ma, Rui and Zhang, Pei and Yao, Guiqing and Li, Xin},
  title = {Patient versus physician preferences for lipid‐lowering drug therapy: A discrete choice experiment},
  journal = {Health Expectations},
  year = {2024},
  volume = {27},
  number = {2},
  doi = {10.1111/hex.14043}
}
Start for free →